BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 30841738)

  • 1. The Expanding Role of Real-World Evidence Trials in Health Care Decision Making.
    Klonoff DC
    J Diabetes Sci Technol; 2020 Jan; 14(1):174-179. PubMed ID: 30841738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
    Webster J; Smith BD
    Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of real-world evidence for oncology clinical decision making in emerging economies.
    Petracci F; Ghai C; Pangilinan A; Suarez LA; Uehara R; Ghosn M
    Future Oncol; 2021 Aug; 17(22):2951-2960. PubMed ID: 34044583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project.
    Franklin JM; Pawar A; Martin D; Glynn RJ; Levenson M; Temple R; Schneeweiss S
    Clin Pharmacol Ther; 2020 Apr; 107(4):817-826. PubMed ID: 31541454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-World Evidence: A Primer.
    Dang A
    Pharmaceut Med; 2023 Jan; 37(1):25-36. PubMed ID: 36604368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.
    Zisis K; Pavi E; Geitona M; Athanasakis K
    J Pharm Pharm Sci; 2024; 27():12302. PubMed ID: 38481726
    [No Abstract]   [Full Text] [Related]  

  • 9. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
    Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
    Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?
    Khosla S; White R; Medina J; Ouwens M; Emmas C; Koder T; Male G; Leonard S
    F1000Res; 2018; 7():111. PubMed ID: 30026923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
    Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
    Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Evidence Should Be Used in Regulatory Decisions About New Pharmaceutical and Medical Device Products for Diabetes.
    Klonoff DC; Gutierrez A; Fleming A; Kerr D
    J Diabetes Sci Technol; 2019 Nov; 13(6):995-1000. PubMed ID: 30943790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
    Thompson D
    Value Health; 2021 Jan; 24(1):112-115. PubMed ID: 33431143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making.
    Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Mullins CD
    Value Health; 2017 Sep; 20(8):1003-1008. PubMed ID: 28964430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How can real-world evidence aid decision making during the life cycle of nonprescription medicines?
    Csoke E; Landes S; Francis MJ; Ma L; Teotico Pohlhaus D; Anquez-Traxler C
    Clin Transl Sci; 2022 Jan; 15(1):43-54. PubMed ID: 34405554
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Payer perceptions of the use of real-world evidence in oncology-based decision making.
    Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
    [No Abstract]   [Full Text] [Related]  

  • 17. Replication of randomized clinical trial results using real-world data: paving the way for effectiveness decisions.
    Sheffield KM; Dreyer NA; Murray JF; Faries DE; Klopchin MN
    J Comp Eff Res; 2020 Oct; 9(15):1043-1050. PubMed ID: 32914653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world evidence to support regulatory decision making: New or expanded medical product indications.
    Franklin JM; Liaw KL; Iyasu S; Critchlow CW; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):685-693. PubMed ID: 33675248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making.
    Berger ML; Sox H; Willke RJ; Brixner DL; Eichler HG; Goettsch W; Madigan D; Makady A; Schneeweiss S; Tarricone R; Wang SV; Watkins J; Daniel Mullins C
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1033-1039. PubMed ID: 28913966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence and product development: Opportunities, challenges and risk mitigation.
    Naidoo P; Bouharati C; Rambiritch V; Jose N; Karamchand S; Chilton R; Leisegang R
    Wien Klin Wochenschr; 2021 Aug; 133(15-16):840-846. PubMed ID: 33837463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.